Figure 1. The 18A queue by month of latest Application Proof, coloured by the modality of each applicant's lead asset. Solid ...
The launch gives Korean pharma, biotech and medical device manufacturers a life sciences-specific, cloud-based system for one ...
Initial PRECISE-SG100K findings from 10,000 participants reveal previously unreported links between genetic variation and ...
The participating investors cited CLD-001's development progress and its therapeutic potential as key factors in their investment decisions. The new participation from pharmaceutical companies ...
Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), a non-covalent ...
CSL and Alentis Therapeutics announced they have entered into an exclusive global collaboration agreement to co-develop and co-promote lixudebart, which has the potential to become a first-in-class ...
Phase 1/2 RAINFOL-01 data show a 45.9% objective response rate and 12.1-month median duration of response, with antitumour activity observed regardless of FRα expression levels. Treatment with Rina-S ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results